Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Crit Care ; 17(6): R287, 2013 Dec 10.
Article in English | MEDLINE | ID: mdl-24321376

ABSTRACT

INTRODUCTION: Septic syndromes remain the leading cause of mortality in intensive care units (ICU). Septic patients rapidly develop immune dysfunctions, the intensity and duration of which have been linked with deleterious outcomes. Decreased mRNA expressions of major histocompatibility complex (MHC) class II-related genes have been reported after sepsis. We investigated whether their mRNA levels in whole blood could predict mortality in septic shock patients. METHODS: A total of 93 septic shock patients were included. On the third day after shock, the mRNA expressions of five MHC class II-related genes (CD74, HLA-DRA, HLA-DMB, HLA-DMA, CIITA) were measured by qRT-PCR and monocyte human leukocyte antigen-DR (mHLA-DR) by flow cytometry. RESULTS: A significant correlation was found among MHC class II related gene expressions. Among mRNA markers, the best prognostic value was obtained for CD74 (HLA-DR antigen-associated invariant chain). For this parameter, the area under the receiver operating characteristic curve (AUC) was calculated (AUC = 0.67, 95% confidence interval (CI) = 0.55 to 0.79; P = 0.01) as well as the optimal cut-off value. After stratification based on this threshold, survival curves showed that a decreased CD74 mRNA level was associated with increased mortality after septic shock (Log rank test, P = 0.0043, Hazard Ratio = 3.0, 95% CI: 1.4 to 6.5). Importantly, this association remained significant after multivariate logistic regression analysis including usual clinical confounders (that is, severity scores, P = 0.026, Odds Ratio = 3.4, 95% CI: 1.2 to 9.8). CONCLUSION: Decreased CD74 mRNA expression significantly predicts 28-day mortality after septic shock. After validation in a larger multicentric study, this biomarker could become a robust predictor of death in septic patients.


Subject(s)
Antigens, CD/blood , Antigens, Differentiation, B-Lymphocyte/blood , HLA-DR Antigens/blood , Histocompatibility Antigens Class II/blood , Shock, Septic/blood , Shock, Septic/mortality , Aged , Biomarkers/blood , Female , Hospital Mortality , Humans , Male , Middle Aged , RNA, Messenger/blood
2.
Crit Care ; 15(5): R252, 2011.
Article in English | MEDLINE | ID: mdl-22027436

ABSTRACT

INTRODUCTION: It is now well accepted that sepsis is associated with the development of a pronounced immunosuppressive state, characterized by severe immune alterations (e.g. reduced proliferative capacity, endotoxin tolerance, apoptosis) participating in increased mortality and susceptibility to nosocomial infections. Efforts are currently aimed at restoring a functional immune response in septic patients. Successful therapy depends on the identification of appropriate immunostimulatory drugs and on the development of suitable biomarkers that could be used to stratify patients and to follow response to treatment. METHODS: In this study, we evaluated the ex vivo effect of recombinant interferon gamma (rIFN-γ) in restoring monocyte functionality (endotoxin-induced Tumor Necrosis Factor-α production) in a two-hit model of endotoxin tolerance (ET) with peripheral blood mononuclear cells from healthy volunteers and in whole blood of septic shock patients. Importantly, we used quantitative-reverse transcription polymerase-chain reaction to monitor the effect of rIFN-γ on the expression of seven genes known to participate in ET (TNF-α, IL-10, HLA-DRA, CIITA, IRAK-M, ABIN-3 and LY64). RESULTS: Expression analysis of those genes confirmed the presence of an immunosuppression state and the ex vivo restoration of immune functions by rIFN-γ. We show for the first time that rIFN-γ is able to bypass, at the mRNA level, the effect of negative regulators of the LPS signalling pathway such as IRAK-M, ABIN-3 and LY64. CONCLUSIONS: Overall, mRNA expressions of a panel of genes could represent promising candidates for the ex vivo evaluation of rIFN-γ effect on monocyte functionality. This ex vivo translational research study demonstrates the potential of a mRNA-based approach to successfully monitor drug efficacy.


Subject(s)
Immune Tolerance/drug effects , Immunotherapy/methods , Interferon-gamma/pharmacology , Lipopolysaccharides/metabolism , Monocytes/drug effects , RNA, Messenger/blood , Shock, Septic/therapy , Aged , Biomarkers, Pharmacological/blood , Case-Control Studies , Female , Humans , Immune Tolerance/genetics , Lipopolysaccharides/immunology , Male , Middle Aged , Monocytes/physiology , Recombinant Proteins/pharmacology , Shock, Septic/blood , Shock, Septic/immunology , Treatment Outcome
3.
J Immunol Methods ; 328(1-2): 220-5, 2007 Dec 01.
Article in English | MEDLINE | ID: mdl-17884081

ABSTRACT

Genomic DNA extraction for genotyping analysis is performed from blood samples and is time consuming. We describe a more rapid DNA extraction method, "DBS-miniMAG", that combines filter paper dried blood spots (DBS) with the NucliSens miniMAG semi-automated instrument (bioMérieux). To assess the performance of this method, a post-PCR HLA-DR shared epitope (SE) oligotyping assay was used as a read-out in a cohort of 72 arthritis patients. This new method was compared to the standard manual DBS extraction protocol using FTA reagents (Whatmann Bio-Science), and to a reference phenol-chloroform-based method using EDTA whole blood samples. Higher yield of PCR amplicons was observed with DNA extracts obtained using "DBS-miniMAG" method. The intra- and inter-assay variability of the "DBS-miniMAG" method was similar to that obtained with "DBS-FTA" washing process. Concerning the HLA-DR SE genotyping, "DBS-miniMAG" and "DBS-FTA" methods gave 100% concordance compared to the reference phenol-chloroform method. More importantly, the hands-on time and the turnaround time for "DBS-miniMAG" were both two-times shorter than for "DBS-FTA" protocol. Therefore, the "DBS-miniMAG" combination could facilitate polymorphism analysis in routine clinical practice and the creation of large DNA banks using very small amounts of blood.


Subject(s)
Arthritis, Rheumatoid/blood , Blood Specimen Collection , DNA/isolation & purification , Epitopes/blood , HLA-DR Antigens/genetics , Hematologic Tests/methods , Arthritis, Rheumatoid/genetics , Blood Specimen Collection/methods , DNA/blood , Epitopes/genetics , Female , Humans , Male , Middle Aged , Polymerase Chain Reaction , Polymorphism, Genetic , Reproducibility of Results , Time
4.
Intensive Care Med ; 43(7): 1013-1020, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28477143

ABSTRACT

PURPOSE: Intensive care unit (ICU)-acquired infections (IAI) result in increased hospital and ICU stay, costs and mortality. To date, no biomarker has shown sufficient evidence and ease of application in clinical routine for the identification of patients at risk of IAI. We evaluated the association of the systemic mRNA expression of two host response biomarkers, CD74 and IL10, with IAI occurrence in a large cohort of ICU patients. METHODS: ICU patients were prospectively enrolled in a multicenter cohort study. Whole blood was collected on the day of admission (D1) and on day 3 (D3) and day 6 (D6) after admission. Patients were screened daily for IAI occurrence and data were censored after IAI diagnosis. mRNA expression levels of biomarkers were measured using RT-qPCR. Fine and Gray competing risk models were used to assess the association between gene expression and IAI occurrence. RESULTS: A total of 725 patients were analyzed. At least one IAI episode occurred in 137 patients (19%). After adjustment for shock and sepsis status at admission, CD74 and IL10 levels were found to be significantly associated with IAI occurrence [subdistribution hazard ratio (95% confidence interval) 0.67 (0.46-0.97) for CD74 D3/D1 expression ratio and 2.21 (1.63-3.00) for IL10 at D3]. IAI cumulative incidence was significantly different between groups stratified according to CD74 or IL10 expression (Gray tests p < 0.001). CONCLUSION: Our results suggest that two immune biomarkers, CD74 and IL10, could be relevant tools for the identification of IAI risk in ICU patients.


Subject(s)
Antigens, Differentiation, B-Lymphocyte/blood , Cross Infection/epidemiology , Histocompatibility Antigens Class II/blood , Intensive Care Units , Interleukin-10/blood , RNA, Messenger/metabolism , Adult , Antigens, Differentiation, B-Lymphocyte/genetics , Biomarkers/blood , Cross Infection/diagnosis , Female , Gene Expression Regulation , Histocompatibility Antigens Class II/genetics , Hospitalization , Humans , Incidence , Intensive Care Units/statistics & numerical data , Interleukin-10/genetics , Male , Prospective Studies , RNA, Messenger/blood , Reverse Transcriptase Polymerase Chain Reaction , Risk Assessment
5.
PLoS One ; 8(7): e68218, 2013.
Article in English | MEDLINE | ID: mdl-23874546

ABSTRACT

The rapid development in septic patients of features of marked immunosuppression associated with increased risk of nosocomial infections and mortality represents the rational for the initiation of immune targeted treatments in sepsis. However, as there is no clinical sign of immune dysfunctions, the current challenge is to develop biomarkers that will help clinicians identify the patients that would benefit from immunotherapy and monitor its efficacy. Using an in vitro model of endotoxin tolerance (ET), a pivotal feature of sepsis-induced immunosuppression in monocytes, we identified using gene expression profiling by microarray a panel of transcripts associated with the development of ET which expression was restored after immunostimulation with interferon-gamma (IFN-γ). These results were confirmed by qRT-PCR. Importantly, this short-list of markers was further evaluated in patients. Of these transcripts, six (TNFAIP6, FCN1, CXCL10, GBP1, CXCL5 and PID1) were differentially expressed in septic patients' blood compared to healthy blood upon ex vivo LPS stimulation and were restored by IFN-γ. In this study, by combining a microarray approach in an in vitro model and a validation in clinical samples, we identified a panel of six new transcripts that could be used for the identification of septic patients eligible for IFNg therapy. Along with the previously identified markers TNFa, IL10 and HLA-DRA, the potential value of these markers should now be evaluated in a larger cohort of patients. Upon favorable results, they could serve as stratification tools prior to immunostimulatory treatment and to monitor drug efficacy.


Subject(s)
Endotoxins/immunology , Immune Tolerance/immunology , Interferon-gamma/immunology , Sepsis/immunology , Shock, Septic/immunology , Aged , Biomarkers/blood , Cross Infection/blood , Cross Infection/genetics , Cross Infection/immunology , Drug Tolerance , Female , HLA-DR alpha-Chains/genetics , HLA-DR alpha-Chains/metabolism , Humans , Immune Tolerance/genetics , Immunosuppression Therapy/methods , Immunotherapy/methods , Interleukin-10/genetics , Interleukin-10/immunology , Lipopolysaccharides/immunology , Male , Middle Aged , Monocytes/immunology , Sepsis/blood , Sepsis/genetics , Shock, Septic/blood , Shock, Septic/genetics , Transcriptome , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology
SELECTION OF CITATIONS
SEARCH DETAIL